← Back to home

RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH FLT3 ACTIVATING MUTATIONS

Clinical trials for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH FLT3 ACTIVATING MUTATIONS explained in plain language.

Never miss a new study

Get alerted when new RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH FLT3 ACTIVATING MUTATIONS trials appear

Sign up with your email to follow new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH FLT3 ACTIVATING MUTATIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

New hope for leukemia patients who relapse

Disease control Completed

This study tested whether adding a targeted drug called crenolanib to standard chemotherapy could better control a specific type of acute myeloid leukemia (AML) that had returned or not responded to prior treatment. It involved 106 adults aged 75 or younger whose cancer had a spe…

Matched conditions: RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH FLT3 ACTIVATING MUTATIONS

Phase: PHASE3 • Sponsor: Arog Pharmaceuticals, Inc. • Aim: Disease control

Last updated Apr 20, 2026 16:18 UTC

RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH FLT3 ACTIVATING MUTATIONS

Get alerted when new RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH FLT3 ACTIVATING MUTATIONS trials appear

New hope for leukemia patients who relapse